Verastem (NASDAQ:VSTM) executives said the company’s transition to a commercial-stage business accelerated in 2025 following ...

The Q4 earnings report for Verastem (NASDAQ: VSTM) was released on Wednesday, March 4, 2026 at 04:01 PM. Here's what investors need to know about the latest announcement. Verastem beat estimated ...

Verastem Oncology has shared a different spin on what its near-approval treatment for low-grade serous ovarian cancer (LGSOC) could mean for patients, publishing survey results that dig into the ...

Verastem (VSTM) delivered earnings and revenue surprises of -2.04% and +0.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Robert Forrester has resigned as CEO of Verastem. Chief Operating Officer Dan Paterson will lead the company while it looks for a permanent successor for Forrester with commercial chops. Forrester ...

The current quarter saw explicit confirmation of the CO-PACK franchise’s path to self-sustainability in H2 2026 and an extension of the cash runway into H1 2027, compared to the prior quarter’s ...

Verastem, Inc. (NASDAQ:VSTM) Q4 2025 Earnings Call Transcript March 4, 2026 Verastem, Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.49. Operator: Good ...

Analysts are estimating that Verastem will report an earnings per share (EPS) of $-0.50. The market awaits Verastem's announcement, with hopes high for news of surpassing estimates and providing ...

Verastem Oncology is launching a fresh campaign that features resources and management for a specific type of ovarian cancer known as low-grade serous ovarian cancer (LGSOC). With this new initiative, ...

We expect investors to focus on Verastem Oncology’s VSTM progress with the development of its pipeline candidates being studied for various cancer indications when it reports first-quarter 2025 ...

Verastem (VSTM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 164,500 shares of ...